ArticleMedicine2026
Three-decade trends in nonalcoholic fatty liver disease across 204 countries and territories: An age-period-cohort analysis from 1990 to 2021.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading chronic liver disease globally, driven by the rising incidence of obesity, type 2 diabetes, and metabolic syndrome. Despite the increasing burden, most studies focus on prevalence rather than incidence, leaving a gap in understanding temporal patterns of NAFLD incidence. We conducted an age-period-cohort analysis of NAFLD incidence across 204 countries and territories from 1990 to 2021, utilizing data from the Global Burden of Disease Study 2021. Incidence rates were standardized per 100,000 person-years and analyzed by age, sex, region, and socio-demographic index (SDI). The global incidence of NAFLD nearly doubled from 24.9 million cases in 1990 to 48.4 million in 2021. The age-standardized incidence rate in 2021 was 593.28 per 100,000 population (95% confidence interval: 542.72-643.7). Middle SDI regions recorded the highest incidence rate (695/100,000), while low SDI regions had the lowest (483/100,000). The age-period-cohort model indicated a net drift of 0.56% (95% confidence interval: 0.53-0.6) globally. NAFLD incidence has risen substantially over the past 3 decades, particularly in middle-income regions. These findings highlight the need for targeted public health interventions and further research to address the growing global burden of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.